维拉帕米增强猴肾上皮细胞低密度脂蛋白受体活性

本文用放射配体法观察了维拉帕米(Ver)对恒河猴肾上皮细胞LDL受体活性的影响,发现Ver以浓度和时间依赖的方式明显增强受体介导的结合和内移过程,对降解的影响不显著。Ver作用浓度为44 mmol·L~(-1)效应最明显。     

聚维酮碘乳膏治疗足癣的临床研究

目的:观察聚维酮碘乳膏治疗足癣的疗效。方法:将符合入选标准的94例患者随机分两组,治疗组清洁局部后将聚维酮碘乳膏涂敷于患处,bid。对照组予派瑞松霜按照药品说明书使用。两组均疗程3周。对痊愈者随访半年。结果:临床治愈率治疗组64.44%,两组比较U=2.883,P<0.01;有效率治疗组93.33%,两组比较X2=7.866,P<0.01;真菌清除率治疗组94.77%,两组比较X2=0.679,P=0.372;不良反应率治疗组4.44%,两组比较X2=4.0226,P=0.0432;随访半年痊愈者复发率治疗组6.89%(2/29),两组比较X2=3.9455,P=0.0421。结论:聚维酮碘乳膏治疗足癣安全有效。     

碘难治性分化型甲状腺癌的最新研究进展

近年来,作为最常见的恶性肿瘤之一,甲状腺癌的发病率曲线明显上升。分化型甲状腺癌经过手术、¹³¹I放疗及促甲状腺激素抑制等治疗后,大多数患者总体预后良好。但仍有少部分患者对放射性碘治疗不敏感且有1个或多个癌基因的突变,则成为病情进展快、死亡率高的碘难治性分化型甲状腺癌。应用上述的传统治疗手段难以取得满意疗效,本文综述了碘难治性分化型甲状腺癌的诊断及治疗进展,为尽早识别及早期进行靶向治疗等争取必要的时间。     

血清超敏C反应蛋白与尿碘水平联合预测先兆流产患者保胎结局的研究

目的观察血清超敏C反应蛋白(hs-CRP)与尿碘水平联合对先兆流产患者保胎结局的预测效能。方法前瞻性选取海南医学院第二附属医院2018年1月至2020年1月收治的112例先兆流产患者作为研究对象,根据保胎结局将患者分为保胎失败组(n=20)与保胎成功组(n=92)。检测两组入院时各主要指标[甲状腺功能相关指标、血清孕酮(P)、β-人绒毛膜促性腺激素(β-HCG)、hs-CRP、尿碘水平],采用Logistic回归分析各主要指标与先兆流产患者保胎结局的关系,并分析入院时血清hs-CRP、尿碘水平对先兆流产患者保胎结局的预测效能。结果保胎失败组P、β-HCG水平低于保胎成功组,hs-CRP水平高于保胎成功组,合并甲状腺功能异常、尿碘水平异常占比高于保胎成功组(P<0.05)。经Logistic回归分析结果显示,先兆流产患者甲状腺功能异常、hs-CRP表达上调、尿碘水平异常是保胎成功的危险因素(OR>1,P<0.05);先兆流产患者P、β-HCG表达上调是保胎成功的保护因素(OR<1,P<0.05);绘制受试者工作特征(ROC)曲线发现,先兆流产患者hs-CRP...     

A review of tositumomab and I131 tositumomab radioimmunotherapy for the treatment of follicular lymphoma

The CD20 antigen has become a major therapeutic target in the management of follicular and other Bcell non-Hodgkin’s lymphomas. The murine monoclonal antibody, tositumomab, on binding CD20, is able to induce antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis. In addition, when radioiodinated, the antibody exploits the tumour’s sensitivity to ionising radiation by direct targeting of the malignant cell. Tositumomab and Iodine (I¹³¹) tositumomab (Bexxar^®, GlaxoSmithKline, Philadelphia, PA, USA) is administered in two steps. The dosimetric step determines individual patient pharmacokinetics, allowing a patient- specific dose to be calculated. This is followed by the therapeutic step, with administration of the therapeutic dose between 7 and 14 days after the dosimetric dose. Over a decade’s worth of experience in clinical trials has determined the efficacy and safety of the regimen in a variety of clinical ci-rcumstances; establishment of exactly where the regimen fits amongst the algorithm for the management of follicular lymphoma continues.     

碘代谢检测指标评估甲状腺疾病手术治疗患者碘营养状况的价值

目的探讨碘代谢检测指标在甲状腺疾病手术治疗患者碘营养状况评估中的应用价值。方法收集31名健康志愿者和30例甲状腺疾病手术患者术前、术后血清、晨尿和24 h尿标本,应用电感耦合等离子体质谱法检测样本中的碘浓度,比较健康者和患者术前、术后血清碘、晨尿碘、晨尿碘/晨尿肌酐、24 h尿碘和24 h尿碘排泄量的差异,并分析健康者碘代谢检测指标的测定值对世界卫生组织、美国梅奥医学中心和奎斯特诊断公司提供的参考范围的验证率。结果甲状腺疾病术前组的晨尿碘/晨尿肌酐比值显著低于健康对照组(P<0.05),两组其他指标的差异无统计学意义(P均>0.05);患者经手术治疗后血清碘、晨尿碘和24 h尿碘水平均显著高于术前水平(P<0.05);健康对照组各项碘代谢指标的中位数均在3个实验室提供的参考范围内,但仅有血清碘、晨尿碘及41~70岁人群的晨尿碘/晨尿肌酐比值与美国梅奥医学中心提供的参考范围的验证率大于90%;晨尿碘/晨尿肌酐比值的受试者工作特征曲线下面积最大,为0.737。结论晨尿碘/晨尿肌酐比值可能用于甲状腺疾病手术治疗患者碘营养状况的评估。     

L-LWiDose4技术在新生儿先天性心脏病CT血管成像中的临床应用

目的：探讨低X线辐射剂量及低碘浓度等渗对比剂联合iDose4迭代重建技术（L-LWiDose4）在新生儿先天性心脏病CT血管成像（CTA）中的可行性。方法：前瞻性收集2015年1月至2018年3月温州医科大学附属第二医院育英儿童医院新生儿科需行心脏CTA检查的连续102例患者,随机分为2组,采用不同的扫描方案：常规组（A组）53例,采用100 kVp、100 mAs、碘海醇（350 mg I/mL）,重建方式为滤波反投影（FBP）算法;实验组49例,采用80 kVp、80 mAs、碘克沙醇（270 mg I/mL）,根据iDose4迭代算法可以得到iDose4-1～iDose4-7 7组图像,选取iDose4-2～iDose4-6 5组图像,分别记为B组、C组、D组、E组、F组。依据新生儿体质量采取不同的对比剂注射剂量并计算碘摄入量。测量主动脉弓、气管分叉水平降主动脉、肺动脉干及主动脉弓层面两侧胸大肌和竖脊肌CT值,测量气管分叉层面周围空气CT值的标准差（SD）,记为背景噪声,计算信噪比（SNR）和对比噪声比（CNR）,并对图像质量进行主观评价。记录容积CT剂量指数（CTDIvol）和剂量长度乘积（DLP）,并计算有效剂量（ED）和体型特异性剂量评估（SSDE）。以手术或心导管造影为“金标准”,统计并比较各组CTA检查的诊断符合率。结果：实验组CTDIvol、SSDE、DLP、ED较常规组分别降低了57.08%、56.62%、58.31%、56.97%（P＜0.05）。常规组、实验组对比剂碘摄入量分别为（1.83±1.27）g和（1.61± 1.36）g,差异有统计学意义（P＜0.05）。B组、F组图像客观评价不及A组、C组、D组、E组（P＜0.05）。A组、D组、E组图像主观评价差异无统计学意义。常规组、实验各组诊断符合率分别为98.6%、81.6%、87.7%、97.9%、97.9%、96.9%,差异无统计学意义（P＞0.05）。结论：80 kVp、80 mAs、碘克沙醇（270 mg I/mL）联合iDose4迭代重建技术新生儿先天性心脏病CTA检查,在降低患者的电离辐射剂量和对比剂碘剂量的同时,其图像质量能够满足临床诊断需要。     

标准剂量泼尼松联合谷氨酰胺对131I治疗后Graves眼病的保护作用

目的 探讨泼尼松联合谷氨酰胺(2 g/d)对131I治疗后Graves眼病(GO)的保护作用.方法 将行131I治疗伴轻-中度活动性或暂无活动性GO但有高危因素的Graves甲状腺功能亢进患者分为两组,试验组(n=59)治疗后2d开始口服泼尼松(0.44±0.13)mg/kg同时补充谷氨酰胺,泼尼松每2周逐渐减量5 mg至2个月停药;对照组(n=57)泼尼松起始剂量为(0.43±0.14)mg/kg,不补充谷氨酰胺,其余同试验组.评估两组患者治疗后2、4、6个月时GO变化以及不良反应.结果 两组患者基线特征无明显差异,治疗后6个月试验组除突眼度外CAS评分(2.8±0.8 vs.3.5士0.9)、眼球突出度[(19.6±8.1)mm vs.(21.7±3.0)mm]、睑裂宽度[(11.3±2.9)mm vs.(13.8士3.1)mm],改善程度均优于对照组(P＜0.01).两组均无GO新发或者恶化;两组疗效比较差异无统计学意义(P＞0.05).对照组比试验组不良反应更多(63.1％ vs.30.5％,P＜0.01),体质量增加更明显[(3.8±1.8) kg vs.(1.4±1.2)kg,P＜0.01],两组患者收缩压和舒张压均轻度上升[(10±4)mm Hg vs.(9±5)mm Hg,P＞0.05].结论 131I治疗后使用起始约0.4 mg/kg、2个月的泼尼松,同时口服补充谷氨酰胺(2 g/d)能有效改善轻-中度GO,并且有效降低不良反应.     

聊城地区尿碘水平与甲状腺疾病的关系

Objective To investigate relationship between urinary iodine level and thyroid diseases in Liaocheng city.Methods Level of serum TSH,FT3,FT4,TPOAb,TGAb and urinary iodine in thyroid disease group and normal control group was detected respectively.Results The median concentration of urinary iodine in normal control group in Liaocheng was 108μg/L.The median urinary iodine level in patients with thyroid dysfunction and thyroid nodal diseases was higher than that in normal control group(P<0.01).In patients with thyroid dysfunction and thyroid nodal diseases,the concentration of urinary iodine Was above 300μg/L and distribution frequency Was much higher than that in control group(P<0.01).There was no correlation between urinary iodine and thyroid function or thyroid nodule(P>0.05).Conclusions Iodine uptake in Liaocheng is sufficient.Additional uptake of iodine increases the incidence of thyroid diseases.Urine iodine detection helps to guide iodine supplementation in individual.     

Radioactive seed localization of breast lesions: an adequate localization method without seed migration

Preoperative localization is important to optimize the surgical treatment of breast lesions, especially in nonpalpable lesions. Radioactive seed localization (RSL) using iodine-125 is a relatively new approach. To provide accurate guidance to surgery, it is important that the seeds do not migrate after placement. The aim of this study was to assess short-term and long-term seed migration after RSL of breast lesions. In 45 patients, 48 RSL procedures were performed under ultrasound or stereotactic guidance. In the first 12 patients, the lesion was localized with two markers: an iodine-125 seed and a reference marker. In 33 patients, 36 RSL procedures were performed using a single iodine-125 seed. All patients received control mammograms after seed placement and prior to surgery. In the patients with two markers, migration was defined as the difference in the largest distance between the markers observed in the mammograms. For single-marked lesions, migration was assessed by comparing distances between anatomical landmarks in the mammograms. RSL was successful in all patients. Seeds were in-situ for 59.5 days on average (3-136 days). The detection rate during surgery was 100%. Overall, an average seed migration of 0.9 mm (standard deviation 1.0 mm) was observed. Neither differences in lesion type, nor days in situ, type of surgery or radiologic localization method were found to have impact on seed migration. RSL is an accurate preoperative localization method for breast lesions with negligible seed migration, independent of time in-situ.